La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale

Translated title of the contribution: Subcutaneous insulin infusion (CSII) in italy: The third nationa survey

D. Bruttomesso, L. Laviola, G. Lepore, R. Bonfanti, L. Bozzetto, A. Corsi, V. Di Blasi, A. Girelli, G. Grassi, D. Iafusco, I. Rabbone, R. Schiaffini, V. Montani, P. Colleluori, V. Paciotti, P. Alfidi, J. Grosso, S. Tumini, P. Cipriano, E. Vitacolonna & 31 others G. Di Vieste, A. Minnucci, D. Antenucci, G. La Penna, M. Taraborrelli, B. Macerala, G. Citro, G. De Morelli, A. Gnasso, C. Irace, F. Citriniti, N. Lazzaro, M. Bruzzese, F. Mammì, F. De Berardinis, E. Santoro, G. Tornese, E. Faleschini, A. Crinò, M. Cappa, D. Maggi, N. Minuto, V. Fuso, E. Orsi, A. Laurenzi, G. Torchio, E. Cazzaniga, R. A. Rabini, S. Giovanni, A. Rauseo, La lista completa dei componenti del Gruppo è disponibile alla fine dell?articolo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Continuous subcutaneous insulin infusion (CSII) is increasingly being used worldwide, mostly thanks to technical improvements. This study examined the current status of CSII in Italy. Physicians in charge of 272 diabetes centers caring for patients using CSII were sent a questionnaire investigating clinical features, pump technology and management of these patients; a large proportion (217 centers, 79.8%) joined the study. By end-April 2013, data had been collected on 10152 patients treated with CSII; 98.2% had type 1 diabetes, 82.4% were adults, 57% female. Only just over half the centers (59%) managed more than 20 CSII patients each. The distribution of patients varied widely both among and within different regions. The main indication for CSII was the de- sire to improve glycemic control. Dropouts (8.65%) were mainly due to difficulties with pump wearability or non-optimal glycemic control. Among CSII patients 61% used a traditional pump, 39% a sensor augmented pump. Only 68% used the CSII advanced functions and glucose sensors were used twelve days per month on average. Round-the-clock assistance was guaranteed in 81% of centers; a full diabetes team followed patients in only 40% of adult-care centers and 50% of pediatric units. CSII is increasingly used in Italy, by adults and pediatric patients. However, further work is needed to unify treatment strategies throughout the country and to encourage optimal pump use and applications.

Original languageItalian
Pages (from-to)121-129
Number of pages9
JournalGiornale Italiano di Diabetologia e Metabolismo
Volume35
Issue number2
Publication statusPublished - Jun 1 2015

Fingerprint

Subcutaneous Infusions
Italy
Insulin
Pediatrics
Surveys and Questionnaires
Type 1 Diabetes Mellitus
Technology
Physicians
Glucose

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Bruttomesso, D., Laviola, L., Lepore, G., Bonfanti, R., Bozzetto, L., Corsi, A., ... La lista completa dei componenti del Gruppo è disponibile alla fine dell?articolo (2015). La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale. Giornale Italiano di Diabetologia e Metabolismo, 35(2), 121-129.

La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale. / Bruttomesso, D.; Laviola, L.; Lepore, G.; Bonfanti, R.; Bozzetto, L.; Corsi, A.; Di Blasi, V.; Girelli, A.; Grassi, G.; Iafusco, D.; Rabbone, I.; Schiaffini, R.; Montani, V.; Colleluori, P.; Paciotti, V.; Alfidi, P.; Grosso, J.; Tumini, S.; Cipriano, P.; Vitacolonna, E.; Di Vieste, G.; Minnucci, A.; Antenucci, D.; La Penna, G.; Taraborrelli, M.; Macerala, B.; Citro, G.; De Morelli, G.; Gnasso, A.; Irace, C.; Citriniti, F.; Lazzaro, N.; Bruzzese, M.; Mammì, F.; De Berardinis, F.; Santoro, E.; Tornese, G.; Faleschini, E.; Crinò, A.; Cappa, M.; Maggi, D.; Minuto, N.; Fuso, V.; Orsi, E.; Laurenzi, A.; Torchio, G.; Cazzaniga, E.; Rabini, R. A.; Giovanni, S.; Rauseo, A.; La lista completa dei componenti del Gruppo è disponibile alla fine dell?articolo.

In: Giornale Italiano di Diabetologia e Metabolismo, Vol. 35, No. 2, 01.06.2015, p. 121-129.

Research output: Contribution to journalArticle

Bruttomesso, D, Laviola, L, Lepore, G, Bonfanti, R, Bozzetto, L, Corsi, A, Di Blasi, V, Girelli, A, Grassi, G, Iafusco, D, Rabbone, I, Schiaffini, R, Montani, V, Colleluori, P, Paciotti, V, Alfidi, P, Grosso, J, Tumini, S, Cipriano, P, Vitacolonna, E, Di Vieste, G, Minnucci, A, Antenucci, D, La Penna, G, Taraborrelli, M, Macerala, B, Citro, G, De Morelli, G, Gnasso, A, Irace, C, Citriniti, F, Lazzaro, N, Bruzzese, M, Mammì, F, De Berardinis, F, Santoro, E, Tornese, G, Faleschini, E, Crinò, A, Cappa, M, Maggi, D, Minuto, N, Fuso, V, Orsi, E, Laurenzi, A, Torchio, G, Cazzaniga, E, Rabini, RA, Giovanni, S, Rauseo, A & La lista completa dei componenti del Gruppo è disponibile alla fine dell?articolo 2015, 'La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale', Giornale Italiano di Diabetologia e Metabolismo, vol. 35, no. 2, pp. 121-129.
Bruttomesso, D. ; Laviola, L. ; Lepore, G. ; Bonfanti, R. ; Bozzetto, L. ; Corsi, A. ; Di Blasi, V. ; Girelli, A. ; Grassi, G. ; Iafusco, D. ; Rabbone, I. ; Schiaffini, R. ; Montani, V. ; Colleluori, P. ; Paciotti, V. ; Alfidi, P. ; Grosso, J. ; Tumini, S. ; Cipriano, P. ; Vitacolonna, E. ; Di Vieste, G. ; Minnucci, A. ; Antenucci, D. ; La Penna, G. ; Taraborrelli, M. ; Macerala, B. ; Citro, G. ; De Morelli, G. ; Gnasso, A. ; Irace, C. ; Citriniti, F. ; Lazzaro, N. ; Bruzzese, M. ; Mammì, F. ; De Berardinis, F. ; Santoro, E. ; Tornese, G. ; Faleschini, E. ; Crinò, A. ; Cappa, M. ; Maggi, D. ; Minuto, N. ; Fuso, V. ; Orsi, E. ; Laurenzi, A. ; Torchio, G. ; Cazzaniga, E. ; Rabini, R. A. ; Giovanni, S. ; Rauseo, A. ; La lista completa dei componenti del Gruppo è disponibile alla fine dell?articolo. / La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale. In: Giornale Italiano di Diabetologia e Metabolismo. 2015 ; Vol. 35, No. 2. pp. 121-129.
@article{c6400ff75a4846fb993d3d5cf7c942e1,
title = "La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale",
abstract = "Continuous subcutaneous insulin infusion (CSII) is increasingly being used worldwide, mostly thanks to technical improvements. This study examined the current status of CSII in Italy. Physicians in charge of 272 diabetes centers caring for patients using CSII were sent a questionnaire investigating clinical features, pump technology and management of these patients; a large proportion (217 centers, 79.8{\%}) joined the study. By end-April 2013, data had been collected on 10152 patients treated with CSII; 98.2{\%} had type 1 diabetes, 82.4{\%} were adults, 57{\%} female. Only just over half the centers (59{\%}) managed more than 20 CSII patients each. The distribution of patients varied widely both among and within different regions. The main indication for CSII was the de- sire to improve glycemic control. Dropouts (8.65{\%}) were mainly due to difficulties with pump wearability or non-optimal glycemic control. Among CSII patients 61{\%} used a traditional pump, 39{\%} a sensor augmented pump. Only 68{\%} used the CSII advanced functions and glucose sensors were used twelve days per month on average. Round-the-clock assistance was guaranteed in 81{\%} of centers; a full diabetes team followed patients in only 40{\%} of adult-care centers and 50{\%} of pediatric units. CSII is increasingly used in Italy, by adults and pediatric patients. However, further work is needed to unify treatment strategies throughout the country and to encourage optimal pump use and applications.",
keywords = "Continuous subcutaneous insulin infusion, Diabetes mellitus, Insulin pump",
author = "D. Bruttomesso and L. Laviola and G. Lepore and R. Bonfanti and L. Bozzetto and A. Corsi and {Di Blasi}, V. and A. Girelli and G. Grassi and D. Iafusco and I. Rabbone and R. Schiaffini and V. Montani and P. Colleluori and V. Paciotti and P. Alfidi and J. Grosso and S. Tumini and P. Cipriano and E. Vitacolonna and {Di Vieste}, G. and A. Minnucci and D. Antenucci and {La Penna}, G. and M. Taraborrelli and B. Macerala and G. Citro and {De Morelli}, G. and A. Gnasso and C. Irace and F. Citriniti and N. Lazzaro and M. Bruzzese and F. Mamm{\`i} and {De Berardinis}, F. and E. Santoro and G. Tornese and E. Faleschini and A. Crin{\`o} and M. Cappa and D. Maggi and N. Minuto and V. Fuso and E. Orsi and A. Laurenzi and G. Torchio and E. Cazzaniga and Rabini, {R. A.} and S. Giovanni and A. Rauseo and {La lista completa dei componenti del Gruppo {\`e} disponibile alla fine dell?articolo}",
year = "2015",
month = "6",
day = "1",
language = "Italian",
volume = "35",
pages = "121--129",
journal = "Giornale Italiano di Diabetologia",
issn = "1593-6104",
publisher = "UTET Periodici Scientifici srl",
number = "2",

}

TY - JOUR

T1 - La terapia insulinica sottocutanea continua (CSII) in Italia. Terza indagine nazionale

AU - Bruttomesso, D.

AU - Laviola, L.

AU - Lepore, G.

AU - Bonfanti, R.

AU - Bozzetto, L.

AU - Corsi, A.

AU - Di Blasi, V.

AU - Girelli, A.

AU - Grassi, G.

AU - Iafusco, D.

AU - Rabbone, I.

AU - Schiaffini, R.

AU - Montani, V.

AU - Colleluori, P.

AU - Paciotti, V.

AU - Alfidi, P.

AU - Grosso, J.

AU - Tumini, S.

AU - Cipriano, P.

AU - Vitacolonna, E.

AU - Di Vieste, G.

AU - Minnucci, A.

AU - Antenucci, D.

AU - La Penna, G.

AU - Taraborrelli, M.

AU - Macerala, B.

AU - Citro, G.

AU - De Morelli, G.

AU - Gnasso, A.

AU - Irace, C.

AU - Citriniti, F.

AU - Lazzaro, N.

AU - Bruzzese, M.

AU - Mammì, F.

AU - De Berardinis, F.

AU - Santoro, E.

AU - Tornese, G.

AU - Faleschini, E.

AU - Crinò, A.

AU - Cappa, M.

AU - Maggi, D.

AU - Minuto, N.

AU - Fuso, V.

AU - Orsi, E.

AU - Laurenzi, A.

AU - Torchio, G.

AU - Cazzaniga, E.

AU - Rabini, R. A.

AU - Giovanni, S.

AU - Rauseo, A.

AU - La lista completa dei componenti del Gruppo è disponibile alla fine dell?articolo

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Continuous subcutaneous insulin infusion (CSII) is increasingly being used worldwide, mostly thanks to technical improvements. This study examined the current status of CSII in Italy. Physicians in charge of 272 diabetes centers caring for patients using CSII were sent a questionnaire investigating clinical features, pump technology and management of these patients; a large proportion (217 centers, 79.8%) joined the study. By end-April 2013, data had been collected on 10152 patients treated with CSII; 98.2% had type 1 diabetes, 82.4% were adults, 57% female. Only just over half the centers (59%) managed more than 20 CSII patients each. The distribution of patients varied widely both among and within different regions. The main indication for CSII was the de- sire to improve glycemic control. Dropouts (8.65%) were mainly due to difficulties with pump wearability or non-optimal glycemic control. Among CSII patients 61% used a traditional pump, 39% a sensor augmented pump. Only 68% used the CSII advanced functions and glucose sensors were used twelve days per month on average. Round-the-clock assistance was guaranteed in 81% of centers; a full diabetes team followed patients in only 40% of adult-care centers and 50% of pediatric units. CSII is increasingly used in Italy, by adults and pediatric patients. However, further work is needed to unify treatment strategies throughout the country and to encourage optimal pump use and applications.

AB - Continuous subcutaneous insulin infusion (CSII) is increasingly being used worldwide, mostly thanks to technical improvements. This study examined the current status of CSII in Italy. Physicians in charge of 272 diabetes centers caring for patients using CSII were sent a questionnaire investigating clinical features, pump technology and management of these patients; a large proportion (217 centers, 79.8%) joined the study. By end-April 2013, data had been collected on 10152 patients treated with CSII; 98.2% had type 1 diabetes, 82.4% were adults, 57% female. Only just over half the centers (59%) managed more than 20 CSII patients each. The distribution of patients varied widely both among and within different regions. The main indication for CSII was the de- sire to improve glycemic control. Dropouts (8.65%) were mainly due to difficulties with pump wearability or non-optimal glycemic control. Among CSII patients 61% used a traditional pump, 39% a sensor augmented pump. Only 68% used the CSII advanced functions and glucose sensors were used twelve days per month on average. Round-the-clock assistance was guaranteed in 81% of centers; a full diabetes team followed patients in only 40% of adult-care centers and 50% of pediatric units. CSII is increasingly used in Italy, by adults and pediatric patients. However, further work is needed to unify treatment strategies throughout the country and to encourage optimal pump use and applications.

KW - Continuous subcutaneous insulin infusion

KW - Diabetes mellitus

KW - Insulin pump

UR - http://www.scopus.com/inward/record.url?scp=84934754052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934754052&partnerID=8YFLogxK

M3 - Articolo

VL - 35

SP - 121

EP - 129

JO - Giornale Italiano di Diabetologia

JF - Giornale Italiano di Diabetologia

SN - 1593-6104

IS - 2

ER -